Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Relationship between cell-mediated immunity to Varicella-Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study.

Shirane R, Tang H, Hayashi K, Okuno Y, Iso H, Asada H, Yamanishi K, Mori Y; SHEZ study group.

J Med Virol. 2017 Feb;89(2):313-317. doi: 10.1002/jmv.24629. Epub 2016 Jul 29.

PMID:
27420414
2.

Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjects.

Tyring SK, Stek JE, Smith JG, Xu J, Pagnoni M, Chan IS, Silber JL, Parrino J, Levin MJ.

Clin Vaccine Immunol. 2012 Sep;19(9):1411-5. doi: 10.1128/CVI.00095-12. Epub 2012 Jul 11.

3.

Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.

Hayashida K, Ozaki T, Nishimura N, Gotoh K, Funahashi K, Nakane K, Gomi Y, Manabe S, Ishikawa T, Yamanishi K.

J Immunol Methods. 2015 Nov;426:50-5. doi: 10.1016/j.jim.2015.07.011. Epub 2015 Jul 29.

PMID:
26232696
4.

Varicella-zoster virus-specific cell-mediated immunity in Ramsay Hunt syndrome.

Haginomori S, Ichihara T, Mori A, Kanazawa A, Kawata R, Tang H, Mori Y.

Laryngoscope. 2016 Jan;126(1):E35-9. doi: 10.1002/lary.25441. Epub 2015 Jul 15.

PMID:
26183571
5.

An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain.

Asada H, Nagayama K, Okazaki A, Mori Y, Okuno Y, Takao Y, Miyazaki Y, Onishi F, Okeda M, Yano S, Kumihashi H, Gomi Y, Maeda K, Ishikawa T, Iso H, Yamanishi K; Shozu Herpes Zoster (SHEZ) Study group.

J Dermatol Sci. 2013 Mar;69(3):243-9. doi: 10.1016/j.jdermsci.2012.10.015. Epub 2012 Nov 5.

PMID:
23183011
6.

Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay.

Sadaoka K, Okamoto S, Gomi Y, Tanimoto T, Ishikawa T, Yoshikawa T, Asano Y, Yamanishi K, Mori Y.

J Infect Dis. 2008 Nov 1;198(9):1327-33. doi: 10.1086/592219.

PMID:
18774884
7.

Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.

Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A.

J Infect Dis. 2016 Jan 1;213(1):14-22. doi: 10.1093/infdis/jiv480. Epub 2015 Oct 9.

PMID:
26452397
8.

Varicella-zoster virus-specific cell-mediated immunity in subjects with herpes zoster.

Otani N, Yamanishi K, Sakaguchi Y, Imai Y, Shima M, Okuno T.

J Immunol Methods. 2012 Mar 30;377(1-2):53-5. doi: 10.1016/j.jim.2012.01.003. Epub 2012 Jan 12.

PMID:
22261191
9.

Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.

Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ.

J Infect Dis. 2003 Nov 1;188(9):1336-44. Epub 2003 Oct 17.

PMID:
14593591
10.

Major depressive disorder and immunity to varicella-zoster virus in the elderly.

Irwin MR, Levin MJ, Carrillo C, Olmstead R, Lucko A, Lang N, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Johnson G, Oxman MN.

Brain Behav Immun. 2011 May;25(4):759-66. doi: 10.1016/j.bbi.2011.02.001. Epub 2011 Feb 15.

11.

A community-based survey of varicella-zoster virus-specific immune responses in the elderly.

Tang H, Moriishi E, Okamoto S, Okuno Y, Iso H, Asada H, Yamanishi K, Mori Y; Shozu Herpes Zoster Study group.

J Clin Virol. 2012 Sep;55(1):46-50. Epub 2012 Jul 6.

PMID:
22771002
12.

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2009 Oct 1;200(7):1068-77. doi: 10.1086/605611.

13.

Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.

Kim JW, Min CK, Mun YC, Park Y, Kim BS, Nam SH, Koh Y, Kwon JH, Choe PG, Park WB, Kim I.

J Clin Virol. 2015 Dec;73:64-69. doi: 10.1016/j.jcv.2015.10.018. Epub 2015 Oct 24.

PMID:
26546878
14.

Varicella-zoster virus-specific cell-mediated immune responses in HIV-infected adults.

De Castro N, Carmagnat M, Kernéis S, Scieux C, Rabian C, Molina JM.

AIDS Res Hum Retroviruses. 2011 Oct;27(10):1089-97. doi: 10.1089/AID.2010.0340. Epub 2011 May 4.

PMID:
21417759
15.

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators.

J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.

16.

VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia.

Imoto K, Okazaki A, Onishi F, Miyazaki Y, Okeda M, Yano S, Takao Y, Gomi Y, Ishikawa T, Okuno Y, Mori Y, Iso H, Yamanishi K, Asada H; SHEZ study group.

J Dermatol Sci. 2015 Sep;79(3):235-40. doi: 10.1016/j.jdermsci.2015.05.011. Epub 2015 Jun 1.

PMID:
26070505
17.

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.

Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schödel FP, Annunziato PW, Schlienger K, Silber JL.

Vaccine. 2012 Jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. Epub 2011 Dec 7.

PMID:
22154769
18.

Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications.

Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, Carrillo C, Stanley HA, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Zhang JH, Johnson G, Oxman MN.

Clin Infect Dis. 2013 Apr;56(8):1085-93. doi: 10.1093/cid/cis1208. Epub 2013 Feb 13.

19.

Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents.

Ogunjimi B, Smits E, Hens N, Hens A, Lenders K, Ieven M, Van Tendeloo V, Van Damme P, Beutels P.

Viral Immunol. 2011 Apr;24(2):151-7. doi: 10.1089/vim.2010.0031.

PMID:
21449725
20.

Assessment of skin test with varicella-zoster virus antigen for predicting the risk of herpes zoster.

Okuno Y, Takao Y, Miyazaki Y, Ohnishi F, Okeda M, Yano S, Kumihashi H, Gomi Y, Maeda K, Ishikawa T, Mori Y, Asada H, Iso H, Yamanishi K; Shozu Herpes Zoster (SHEZ) Study Group.

Epidemiol Infect. 2013 Apr;141(4):706-13. doi: 10.1017/S0950268812002671. Epub 2012 Dec 10.

PMID:
23218021

Supplemental Content

Support Center